Galectin-3 as a prognostic biomarker for diabetic nephropathy
Authors Hodeib H, Hagras MM, Abdelhai D, Watany MM, Selim A, Tawfik MA, Elsebaey MA, Elshweikh SA
Received 13 November 2018
Accepted for publication 31 January 2019
Published 13 March 2019 Volume 2019:12 Pages 325—331
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Andrew Yee
Peer reviewer comments 2
Editor who approved publication: Dr Steven F. Abcouwer
Hossam Hodeib,1 Maha M Hagras,1 Dina Abdelhai,1 Mona M Watany,1 Amal Selim,2 Mohamed A Tawfik,2 Mohamed A Elsebaey,2 Samah A Elshweikh2
1Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Internal Medicine Department, Faculty of Medicine, Tanta University, Tanta, Egypt
Introduction: Diabetic nephropathy (DN) represents one of the main causes of end-stage renal disease in type 2 diabetes mellitus (DM) patients. Galectin-3 has been implicated in pathogenesis of many pathological conditions. To date, there are limited data regarding the relationship between galectin-3 and DN.
Aim of the study: Evaluation of serum galectin-3 as a novel prognostic biomarker in patients with DN.
Patients and methods: This prospective study was carried out in the Internal Medicine and Clinical Pathology Departments, Tanta University Hospital, Egypt, from March 2015 to March 2018 on 300 patients with type 2 DM. Patients were divided into three groups: group I included 100 patients with albumin/creatinine ratio (ACR) 300 mg/g (macroalbuminuria). All patients were subjected to the following: full history taking, clinical examination, and laboratory evaluation (HbA1c, creatinine, estimated glomerular filtration rate, ACR, and serum galectin-3).
Results: The mean levels of galectin-3 were significantly higher in patients with macroalbuminuria than in those with microalbuminuria and normoalbuminuria. Galectin-3 was a significant predictor for progression to microalbuminuria, macroalbuminuria, dialysis, and death among patients with type 2 DM.
Conclusion: Based on this single center prospective study, serum galectin-3 is considered a significant predictor for DN progression among patients with type 2 DM.
Keywords: diabetic nephropathy, galectin-3, albumin/creatinine ratio, microalbuminuria, macroalbuminuria, dialysis, diabetes mellitus
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]